Table 1.
Baseline Demographics and Disease Characteristics per Independent Central Radiology Review
| Characteristic | Everolimus |
|---|---|
| Total No. | 28 |
| Median age, yr (range) | 11.0 (3−34) |
| Age categories, No. [%] | |
| 3 to < 12 years | 16 [57.1] |
| ≥12 to < 18 years | 6 [21.4] |
| ≥18 years | 6 [21.4] |
| Gender, No. [%] | |
| Male | 17 [60.7] |
| Female | 11 [39.3] |
| Race, No. [%] | |
| White | 24 [85.7] |
| Black/African American | 2 [7.1] |
| Mixed | 2 [7.1] |
| SEGA lesions, No. [%] | |
| 1 | 15 [53.6] |
| 2 | 13 [46.4] |
| Bilateral SEGA, No. [%] | 12 [42.9] |
| Parenchymal invasion, No. [%] | |
| Superficial | 25 [89.3] |
| Deep | 2 [7.1] |
| None | 1 [3.6] |
| Hydrocephalus, No. [%] | 6 [21.4] |
| Prior anti‐SEGA therapy, No. [%] | |
| Surgery | 4 [14.3] |
| Systemic therapy | 2 [7.1] |
SEGA = subependymal giant cell astrocytoma.